Synendos Therapeutics is a biopharmaceutical company that aims to develop breakthrough safe and effective therapies for unmet needs in neuropsychiatric disorders through modulation of a new drug target in the endocannabinoid system that enables restoration of natural functioning of the brain.
Our mission is to advance the preclinical and clinical development of a new class of small molecules that act as selective endocannabinoid reuptake inhibitors (SERIs).
SERIs are competitive and reversible first-in-class inhibitors that restore the normal functioning of the endocannabinoid system by increasing the levels of endogenous cannabinoids (endocannabinoids) and represent an innovative therapeutic approach for central nervous system (CNS) disorders.
Our lead programme is focused on high unmet medical needs in the area of anxiety, mood and stress-related disorders. Synendos was founded as a University of Bern and NCCR TransCure spin-off in April 2019. Synendos arises from many years of solid basic research on endocannabinoid biology and pharmacology and a thorough medicinal chemistry programme that led to identification of our preclinical drug candidate SYT-510.
INNOVATIVE APPROACH TO PROVIDE MORE SAFE AND EFFECTIVE THERAPIES FOR CNS DISORDERS
The endocannabinoid system is a key neuromodulator system in the CNS and represents a promising therapeutic target for a wide range of CNS diseases characterized by insufficient endocannabinoid signalling (deficiency).
Selective endocannabinoid reuptake inhibitors (SERIs) can restore normal endocannabinoid tone through the modulation of a newly identified drug target responsible of endocannabinoid cell reuptake.
SERIs can exert pro-homeostatic effects on different neuronal circuits by acting with a self-limiting mechanism of action. At Synendos, we advance the preclinical and clinical development of SYT-510 and two other possible follow up compounds.